Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

This journal activity provides practitioners with the knowledge in understanding whether radiotherapy when given with Cyclin-Dependent Kinase (CDK) 4/6 inhibitors is associated with a different toxicity profile than radiotherapy alone.

Covid-19 rapidly affected our lives and the life of our patients. Vaccination campaign started in 2021. At least four types of vaccines are widely used in the US (Pfizer, Moderna, Johnson and Johnson and Astra Zeneca).

The course consists of two debates. The first debate consists of two thoracic oncologists with one arguing for the use of surgery and one against the use of surgery for patients with stage III NSCLC.

The course presents a review of recent changes in the management of resected NSCLC as well as the management of patients with early stage NSCLC treated with SBRT. The four main topics are:

This panel discussion (part 3) presents on overcoming barriers to come for lung cancer, and includes a pulmonologist, a radiation oncologist, a thoracic surgeon, and a medical oncologist.

This panel discussion (part 2) presents on overcoming barriers to come for lung cancer, and includes a pulmonologist, a radiation oncologist, a thoracic surgeon, and a medical oncologist.

This panel discussion (part 1) presents on overcoming barriers to come for lung cancer, and includes a pulmonologist, a radiation oncologist, a thoracic surgeon, and a medical oncologist.

This education activity is aimed at updating participants with the latest available data regarding the use of radiotherapy for patients with metastatic lung cancer. The primary focus will be on the use of radiotherapy with curative intent for patients with limited metastatic disease.

This activity present on the the topic of: Lung SABR for early stage NSCLC, reviewing patient selection, treatment planning, dose-fractionation followed by challenging aspects such as ultra-central lesions and reirradiation, and Locally advanced (Stage III NSCLC), discussing patient selection for

Pages

Subscribe to RSS - CME only